Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases

作者：Tanaka Toshio; Narazaki Masashi; Kishimoto Tadamitsu^*

来源：FEBS LETTERS, 2011, 585(23): 3699-3709.

DOI：10.1016/j.febslet.2011.03.023

• Tocilizumab
• A humanized anti-IL-6 receptor antibody
• IL-6
• Autoimmune diseases
• Inflammation

Interleukin (IL)-6 is a cytokine with multiple biological activities. It contributes to host defense against pathogens, whereas accelerated production of IL-6 plays a significant pathological role in various diseases. Clinical trials have demonstrated the efficacy of tocilizumab, a humanized anti-IL-6 receptor antibody, for patients with rheumatoid arthritis, Castleman's disease or juvenile idiopathic arthritis, leading to approval of this innovative drug for the treatment of these diseases. Since IL-6 has been demonstrated to play a significant role in the development of various other autoimmune and inflammatory diseases, tocilizumab can be expected to become a novel drug for such diseases as well.

• 出版日期2011-12-1